Zevor-cel (CT053) BCMA CAR-T Cells in Multiple Myeloma

Time: 11:30 am
day: Day Two


  • Reporting the safety and efficacy of zevor-cel CAR-BCMA T cells (CT053) utilizing a newly identified, fully-human BCMA-specific scFv with fine-tuned binding affinity
  • Zevor-cel showed low-level CD3 autophosphorylation and induced relatively lowlevel IL-6 secretion while displaying potent preclinical antitumor activities
  • Sharing results from two registration studies (LUMMICAR-1 in China and LUMMICAR-2 in US and Canada)